



كلية الطب البشري
قسم الامراض الباطنية



جامعة عين شمس

نتائج زراعة خلايا الدم الجذعية من متبرع شقيق متوافق في الأنسجة في المرضى المصابين بالأورام بالغدد الليمفاوية

رسالة

توطئة للحصول علي درجة الماجستير

في امراض الدم

مقدمة من

الطبيب/ آية عبد الحكيم عوض إبراهيم

بكالوريوس الطب والجراحة

تحت إشراف

الأستاذ الدكتور / محمد عثمان عزازى

المسيرى

أستاذ أمراض الباطنة وأمراض الدم الاكلينيكية وزرع النخاع

كلية الطب - جامعة عين شمس

الأستاذ الدكتور / محمد عبد المعطى محمد سمرة

أستاذ طب الأورام وأمراض الدم الاكلينيكية وزرع النخاع

المعهد القومى للأورام- جامعة القاهرة

الدكتورة/ رشا كامل فتحى

مدرس أمراض الباطنة وأمراض الدم الاكلينيكية وزرع النخاع

كلية الطب - جامعة عين شمس

كلية الطب - جامعة عين شمس

٢٠٢٠



*Faculty of Medicine
Department of Internal Medicine*



Ain Shams University

Outcome of Allogeneic Hemopoietic Stem Cell Transplantation in Patients with Lymphoma

Thesis

**Submitted for Partial Fulfilment of
Master Degree in Haematology**

By

Aya Abdelhakim Awad Ibrahim
M.B.B.Ch.

Supervised by

Prof. Dr / Mohamed Osman Azzazi Elmessery

*Professor of Internal Medicine- Clinical Haematology and BMT
Faculty of Medicine, Ain Shams University*

Prof. Dr / Mohamed Abdel-Mooti Mohamed Samra

*Professor of Medical Oncology-Clinical Haematology and BMT
National Cancer Institute, Cairo University*

Dr / Rasha Kamel Fathy

*Lecturer of Internal Medicine- Clinical Haematology and BMT
Faculty of Medicine, Ain Shams University*

**Faculty of Medicine - Ain Shams University
2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to
GOD the Most Beneficent and Merciful.*

I would like to express my indebtedness and deepest gratitude to Prof. Dr / Mohamed Osman Azzazi Elmessery, Professor of Internal Medicine- Clinical Haematology and BMT Faculty of Medicine, Ain Shams University, for his valuable advice, guidance and constructive criticism, also for the valuable assistance and efforts he devoted in the supervision of this study.

I'll never forget, how co-operative was Prof. Dr / Mohamed Abdel-Mooti Mohamed Samra, Professor of Medical Oncology-Clinical Haematology and BMT Faculty of Medicine, Ain Shams University, also he was encouraging all the time. It is honorable to be supervised by him.

I would like also, to express my great thanks to Dr / Rasha Kamel Fathy, Lecturer of Internal Medicine- Clinical Haematology and BMT Faculty of Medicine, Ain Shams University, her valuable advises and continuous support facilitated completing this work.

I would like to thank all the staff members of Department of Internal Medicine.

Finally, I would like to express my appreciation and gratitude to all my family, especially my caring and loving parents who enlighten my life.

Aya Abdelhakim Awad Ibrahim

List of Contents

Title	Page No.
List of Tables.....	6
List of Figures	8
List of Abbreviations.....	10
Abstract	13
Introduction	- 1 -
Aim of the Work	6
Review of Literature	
▪ Indications of Hemopoietic Stem Cells Transplantation.....	7
▪ Diffuse Large B Cell Lymphoma	38
▪ Novel Agent in Lymphoma	88
Patients and Methods.....	125
Results.....	147
Discussion	164
Summary	178
Conclusion	183
Recommendations	184
References	185
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Indications for HCT in pediatric patients (generally age <18 years)	14
Table 2:	Indications for hematopoietic cell transplantation in adults (generally age ≥18 years).....	17
Table 3:	Results of Allo-HSCT	27
Table 4:	Allogeneic HSCT in Burkitt lymphoma.....	30
Table 5:	Allogeneic HSCT.....	31
Table 6:	EMBT current indications for allogeneic HSCT in cHL	32
Table 7:	Results of Allo-HSCT	35
Table 8:	Therapeutic options after allp-HSCT relapse	36
Table 9:	Revised staging system for primary nodal lymphomas.....	41
Table 10:	Lugano criteria for response assessment in lymphoma	49
Table 11:	Lugano criteria for response assessment in lymphoma	57
Table 12:	Classification of Hodgkin lymphomas	69
Table 13:	Distribution of the studied cases according to demographic data (n = 39)	147
Table 14:	Distribution of the studied cases according to diagnosis (n = 39).....	148
Table 15:	Distribution of the studied cases according to A.P (n = 39).....	150
Table 16:	Descriptive analysis of the studied cases according to different parameters (n = 39).....	151
Table 17:	Distribution of the studied cases according to different parameters (n = 39).....	152
Table 18:	Descriptive analysis of the studied cases according to Hospital Stay and CD34 Cells (n = 39)	153

List of Tables cont...

Table No.	Title	Page No.
Table 19:	Descriptive analysis of the studied cases according to CBC (n = 39)	153
Table 20:	Distribution of the studied cases according to cond. (n = 39).....	154
Table 21:	Distribution of the studied cases according to Gvhd PX (n = 39)	154
Table 22:	Distribution of the studied cases according to CMV (n = 39).....	155
Table 23:	Distribution of the studied cases according to different parameters (n = 39).....	156
Table 24:	Kaplan-Meier survival curve for overall survival	158
Table 25:	Relation between AGVHD/2-4 and different parameters (n = 39)	159
Table 26:	Relation between AGVHD/2-4 and different parameters (n = 39)	160
Table 27:	Relation between AGVHD/2-4 and different parameters.....	162

List of Figures

Fig. No.	Title	Page No.
Fig. 1:	Therapeutic Algorithm Recommended by the Authors	28
Fig. 2:	Therapeutic Algorithm Recommended by the Authors	36
Fig. 3:	PCT, prospective clinical trials.	37
Fig. 4:	Long-term outcomes of Allo-HSCT in Patients with Relapsed/Refractory cHL (EBMT Database, with Permission)	37
Fig. 5:	Gastric B cell lymphoma	42
Fig. 6:	Diffused large b cell lymphoma	43
Fig. 7:	Diffused lage b cell lymphoma	44
Fig. 8:	Diffused lage b cell lymphoma BCL-6 staining.....	46
Fig. 9:	Hans and Tally methods for determining cell of origin in Diffused lage b cell lymphoma	58
Fig. 10:	Flow cytometry diffuse lage B cell lymphoma	61
Fig. 11:	Mononuclear Hodgkin cell	76
Fig. 12:	Lacunar cell and mummified reed-sternberg cell	77
Fig. 13:	Comparison of the studied cases according to demographic data	148
Fig. 14:	Comparison of the studied cases according to diagnosis.	149
Fig. 15:	Comparison of the studied cases according to A.P.....	150
Fig. 16:	Descriptive analysis of the studied cases according to different parameters.	151

List of Figures cont...

Fig. No.	Title	Page No.
Fig. 17:	Descriptive analysis of the studied cases according to Mortality.	155
Fig. 18:	Descriptive analysis of the studied cases according to different parameters.	157
Fig. 19:	Kaplan-Meier survival curve for overall survival	158
Fig. 20:	Comparison between studied cases according to Hospital Stay.....	161
Fig. 21:	Comparison between studied cases according to RBCs.	161
Fig. 22:	Comparison between studied cases according to MMF, STD, CMV, Mortality, HCV Ab and HCV PCR.....	163

List of Abbreviations

Abb.	Full term
<i>ABC</i>	<i>Activated B cell</i>
<i>ALCL</i>	<i>Anaplastic large cell lymphoma</i>
<i>ALK</i>	<i>Anaplastic lymphoma kinase</i>
<i>ALL</i>	<i>Acute lymphoblastic leukemia/lymphoma</i>
<i>BCL2</i>	<i>B cell leukemia/lymphoma 2</i>
<i>BCL6</i>	<i>B cell lymphoma 6</i>
<i>BR</i>	<i>Bendamustine plus rituximab</i>
<i>Btk</i>	<i>Btk</i>
<i>BV</i>	<i>Brentuximab vedotin</i>
<i>CAR</i>	<i>Chimeric antigen receptor</i>
<i>Cdk</i>	<i>Cyclin-dependent kinases</i>
<i>cHL</i>	<i>Classic HL</i>
<i>CLL</i>	<i>Chronic lymphocytic leukemia</i>
<i>CR</i>	<i>Complete response</i>
<i>CRS</i>	<i>Cytokine release syndrome</i>
<i>CT</i>	<i>Computed tomography</i>
<i>CTCL</i>	<i>Cutaneous T-cell lymphoma</i>
<i>CTCL</i>	<i>Cutaneous T-cell lymphomas</i>
<i>DLBCL</i>	<i>Diffuse large B cell lymphoma</i>
<i>DLI</i>	<i>Donor lymphocyte infusion</i>
<i>EBV</i>	<i>Epstein-Barr virus</i>
<i>EORTC</i>	<i>European Organization for the Research and Treatment of Cancer</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>FDG</i>	<i>Fluorodeoxyglucose</i>
<i>FISH</i>	<i>Fluorescence in situ hybridization</i>
<i>FL</i>	<i>Follicular lymphoma</i>
<i>GCB</i>	<i>Germinal center B cell</i>
<i>GEP</i>	<i>Gene expression profiling</i>
<i>GHSg</i>	<i>German Hodgkin Study Group</i>

List of Abbreviations cont...

Abb.	Full term
<i>GI</i>	<i>Gastrointestinal</i>
<i>HDAC</i>	<i>Histone deacetylase</i>
<i>HL</i>	<i>Hodgkin lymphomas</i>
<i>HMTs</i>	<i>Histone methyltransferases</i>
<i>HSCI</i>	<i>Hematopoietic stem cell infusion</i>
<i>HSCT CI</i>	<i>HSCT Comorbidity Index</i>
<i>HSCT</i>	<i>Hematopoietic stem cell transplantation</i>
<i>Ig</i>	<i>Immunoglobulin</i>
<i>IHC</i>	<i>Immunohistochemistry</i>
<i>IMT</i>	<i>Inflammatory myofibroblastic tumor</i>
<i>IPS</i>	<i>International prognostic score</i>
<i>LDCHL</i>	<i>Lymphocyte depleted cHL</i>
<i>LDH</i>	<i>Lactate dehydrogenase</i>
<i>LMP</i>	<i>Latent membrane protein</i>
<i>LRCHL</i>	<i>Lymphocyte rich cHL</i>
<i>MCCHL</i>	<i>Mixed cellularity cHL</i>
<i>MCL</i>	<i>Mantle cell lymphoma</i>
<i>MF</i>	<i>Mycosis fungoides</i>
<i>MSD</i>	<i>Matched sibling donor</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>
<i>NHL</i>	<i>Non-Hodgkin lymphoma</i>
<i>NLPHL</i>	<i>Nodular lymphocyte predominant HL</i>
<i>NMDP</i>	<i>National Marrow Donor Program</i>
<i>NRM</i>	<i>Nonrelapse mortality</i>
<i>NSCHL</i>	<i>Nodular sclerosis cHL</i>
<i>OS</i>	<i>Overall survival</i>
<i>PAM</i>	<i>Pre-transplantation Assessment of Mortality</i>
<i>PCR</i>	<i>Polymerase chain reaction</i>
<i>PET</i>	<i>Positron emission tomography</i>
<i>PFS</i>	<i>Progression-free survival</i>

List of Abbreviations cont...

Abb.	Full term
<i>PI3K</i>	<i>Phosphatidyl-inositole3 kynase</i>
<i>PKC</i>	<i>Protein kinase C</i>
<i>PLD</i>	<i>Pegylated Liposomal Doxorubicin</i>
<i>PNP</i>	<i>Purine nucleoside phophoryalse inhibitor</i>
<i>PR</i>	<i>Partial response</i>
<i>REMS</i>	<i>Risk evaluation and mitigation strategy</i>
<i>RIC</i>	<i>Reduced-intensity conditioning</i>
<i>RON</i>	<i>Recepteur d'Origine Nantais</i>
<i>RS</i>	<i>Reed-Sternberg</i>
<i>RT</i>	<i>Radiation therapy</i>
<i>SLL</i>	<i>Small lymphocytic lymphoma</i>
<i>SS</i>	<i>Sezary Syndrome</i>
<i>TdT</i>	<i>Terminal deoxynucleotidyl transferase</i>
<i>T-PLL</i>	<i>T-prolymphocytic leukemia</i>
<i>WHO</i>	<i>World Health Organization</i>

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly used in patients with lymphoma who experience disease relapse after autologous hematopoietic stem cell transplantation (auto-HSCT) because the allograft is tumor free and may induce a graft-versus-tumor effect.

Aim and objectives: Assess the clinical outcome in Egyptian patients diagnosed with lymphomas subjected to hemopoietic allogeneic stem cell transplantation from Human Leukocyte Antigen identical sibling donors.

Subjects and methods: This is A Retrospective study, carried out on 35 patients, at Bone Marrow Transplantation Unit at Nasser Institute Hospital, from May 1997 to August 2018.

Results: There was significant difference between the AGVHD/2–4 yes and no groups as regard MMF, STD, CMV, Mortality, HCV Ab and HCV PCR.

Conclusion: There was significant difference between patients who had the allogeneic transplantation who relapse after the autologous transplantation

Keywords: Allogeneic Stem Cell Transplantation, Lymphoma, Haemodialysis, Autologous Stem Cell Transplantation.

INTRODUCTION

Hematopoietic stem cell transplantation (HSCT) is now established as a standard therapeutic modality for a variety of malignant and non-malignant diseases. The first successful allogeneic HSCT was done with bone marrow (BM) as the source of hematopoietic stem cells in 1968 (*Cheuk et al., 2013*).

Nowadays transplant physicians are faced with 3 viable choices of stem cells for allogeneic HSCT, namely Bone Marrow, Peripheral Blood Stem Cells and Cord Blood and clinicians have to face the challenges of selecting the optimal stem cell source. Although all 3 sources of stem cells are capable of reconstituting the hematopoietic system in recipient after transplant, they have many inherent differences in cellular constituents and biological and immunological properties (*Cheuk et al., 2013*).

Important difference among the sources of stem cell is the amount of mature T cells present. PBSC usually contains a lot more mature T cells compared to BM, which in turn contains more T cells compared to CB, and this partly explains the differences in the risk of graft rejection and graft-versus-host disease (GVHD). Depletion of T cells is associated with increased risk of graft rejection and disease relapse, but lower risk of GVHD (*Switzer et al., 2013*).

G-CSF-mobilized PBSC are increasingly used instead of BM cells for allogeneic transplantation because they provide faster engraftment and better survival in recipients with poor-risk disease (*Group SCTC 2005*). One of the main reasons for preferring PSC worldwide is the important advantages provided by this method to the donor. These advantages are avoidance of anesthesia, lack of the need for hospitalization or blood transfusion, and very low serious adverse event risk (*Itur Sirinoglu Demiriz et al., 2012*).

Most of the randomized controlled trials (RCTs) comparing matched related donor BM and PBSC transplantation for patients with hematological malignancies found no significant differences between the two stem cell source in important outcomes including overall survival, disease-free survival, transplant-related mortality, relapse, acute GVHD and chronic GVHD (*Warren et al., 2000*). However, all trials showed significantly faster neutrophil engraftment in PBSC transplants, and all but one trial showed significantly faster platelet engraftment in PBSC transplants, which may result in earlier hospital discharge for PBSC recipients and lower cost for PBSC transplantation. Lymphocyte recovery was also found to be better in the PBSC group in one trial (*Powles et al., 2000*).

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of hematologic malignancies with varied aggressiveness and many therapeutic options. An estimated 66,360 new cases